Sandra E. Dillahunt

Array ( [id] => 13413275 [patent_doc_number] => 20180258180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/909577 [patent_app_country] => US [patent_app_date] => 2018-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15909577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147809 [patent_doc_number] => 20190352382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => IMMUNE CHECKPOINT THERAPY [patent_app_type] => utility [patent_app_number] => 16/481323 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16481323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858546 [patent_doc_number] => 11439684 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Lymphocyte and monocyte populations in cancer patients and autologous stem cell preparations, and uses thereof [patent_app_type] => utility [patent_app_number] => 16/486863 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 10748 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16486863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15726861 [patent_doc_number] => 10611852 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-07 [patent_title] => Insulin-lipid complex, preparation method therefor, and preparation thereof [patent_app_type] => utility [patent_app_number] => 15/895282 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 8324 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345263 [patent_doc_number] => 20200010523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => Chimera of Bone Morphogenic Protein 2 and the Mullerian-Inhibiting Substance Type II Receptor Binding Region of Mullerian-Inhibiting Substance [patent_app_type] => utility [patent_app_number] => 16/483944 [patent_app_country] => US [patent_app_date] => 2018-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17636126 [patent_doc_number] => 11346846 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-31 [patent_title] => Methods and compositions for diagnosis and prognosis of renal injury and renal failure [patent_app_type] => utility [patent_app_number] => 16/483519 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 161562 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13354709 [patent_doc_number] => 20180228894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => INHIBITION OF CXCR4 SIGNALING IN CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 15/889459 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15889459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383669 [patent_doc_number] => 20180243376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => METHODS AND NON-IMMUNOGENIC COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS [patent_app_type] => utility [patent_app_number] => 15/885432 [patent_app_country] => US [patent_app_date] => 2018-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15885432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808720 [patent_doc_number] => 20180161410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification [patent_app_type] => utility [patent_app_number] => 15/883100 [patent_app_country] => US [patent_app_date] => 2018-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30383 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15883100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15259721 [patent_doc_number] => 20190378594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => Methods of Identifying and Treating Patient Populations Amenable to Cancer Immunotherapy [patent_app_type] => utility [patent_app_number] => 16/479211 [patent_app_country] => US [patent_app_date] => 2018-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8043 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16479211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17650742 [patent_doc_number] => 11353465 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => Methods and compositions for evaluation and treatment of renal injury and renal failure based on C--C motif chemokine ligand 14 measurement [patent_app_type] => utility [patent_app_number] => 16/475326 [patent_app_country] => US [patent_app_date] => 2018-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21663 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 178 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649721 [patent_doc_number] => 20200087390 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => ANTI-TNF ALPHA ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/471492 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16471492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410287 [patent_doc_number] => 20180256686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => Compositions and Methods for Treating Ischemia [patent_app_type] => utility [patent_app_number] => 15/849460 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12909031 [patent_doc_number] => 20180194852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => CHIMERIC THERAPEUTIC ANTI - CD37 ANTIBODIE HH1 [patent_app_type] => utility [patent_app_number] => 15/847667 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15847667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12794965 [patent_doc_number] => 20180156824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => KIDNEY FUNCTION BIOMARKERS [patent_app_type] => utility [patent_app_number] => 15/847111 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15847111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12603438 [patent_doc_number] => 20180092976 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => THERAPEUTIC COMPOSITIONS FOR TREATMENT OF OCULAR INFLAMMATORY DISORDERS [patent_app_type] => utility [patent_app_number] => 15/842604 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15842604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15342623 [patent_doc_number] => 20200009203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => METHODS AND COMPOSITIONS COMPRISING VIRAL GENE THERAPY AND AN IMMUNE CHECKPOINT INHIBITOR FOR TREATMENT AND PREVENTION OF CANCER AND INFECTIOUS DISEASES [patent_app_type] => utility [patent_app_number] => 16/468408 [patent_app_country] => US [patent_app_date] => 2017-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30053 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -113 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16468408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13207137 [patent_doc_number] => 10117919 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-06 [patent_title] => Methods and materials for generating CD8 [patent_app_type] => utility [patent_app_number] => 15/810924 [patent_app_country] => US [patent_app_date] => 2017-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 13 [patent_no_of_words] => 4090 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15810924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15198903 [patent_doc_number] => 10496949 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-03 [patent_title] => Compositions and methods for treating cutaneous conditions [patent_app_type] => utility [patent_app_number] => 15/806300 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 7658 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15806300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17604050 [patent_doc_number] => 11332521 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-17 [patent_title] => Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof [patent_app_type] => utility [patent_app_number] => 16/348058 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 34 [patent_no_of_words] => 46870 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348058 [rel_patent_id] =>[rel_patent_doc_number] =>)